![]() Fulgent's proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. The HelioLiver test continues to be evaluated in Helio's pivotal prospective study, CLiMB ( NCT: 03694600)įor more information about HelioLiver, please visit Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. The poster presentation, titled "A Multi-Analyte Blood Test for Accurate and Early Detection of Hepatocellular Carcinoma," will be available for viewing by the attendees of The Liver Meeting ® beginning November 8, 2021. The study included 122 subjects diagnosed with HCC, 125 control subjects diagnosed with a benign liver disease, and 56 subjects diagnosed with other cancer types. The ENCORE study was a blinded, multicenter validation study using blood specimens drawn from 303 subjects. "Through our partnership with Fulgent Genetics, we look forward to delivering new early cancer diagnostic technologies beginning with HelioLiver in the U.S. "As a result of rigorous scientific evaluations, these new findings underscore HelioLiver's potential to detect liver cancer early and ultimately save lives," said Justin Chen Li, U.S. "These results indicate HelioLiver has significant promise to redefine the standard of care in terms of providing a highly sensitive, easy-to-use blood test for patients and healthcare providers alike." Van Etten, Director of the NCI-designated Chao Family Comprehensive Cancer Center and member of the Division of Hematology/Oncology at the University of California, Irvine. "As one of the fastest growing and deadliest cancers worldwide, it is essential to detect liver cancer as early as possible to initiate treatment intervention to optimize successful patient outcomes," said Dr. A highly sensitive blood test can drive patient adherence to surveillance guidelines and provide a more convenient and cost-effective way to detect HCC. HelioLiver has the potential to reduce morbidity and mortality in HCC patients as there are more curative treatment options when the cancer is found at earlier stages. HelioLiver is a multi-analyte blood test that utilizes both cell-free DNA (cfDNA) methylation patterns and protein tumor markers to detect early-stage HCC with high accuracy. The information on this page is not an endorsement of Truv’s services by Helio Health and is meant to be purely informational.Note: Table denotes HelioLiver sensitivities at 91% specificity 1 ![]() They collaborate with other healthcare organizations and community partners to improve the overall health and well-being of the individuals and communities they serve. Helio Health is funded by a combination of state and federal grants, private donations, and insurance reimbursements. They are committed to providing evidence-based, person-centered care and strive to make their services accessible and affordable to all individuals, regardless of their ability to pay. ![]() Helio Health is accredited by the Commission on Accreditation of Rehabilitation Facilities (CARF) and is recognized as a Center of Excellence in Behavioral Health Services by the National Council for Behavioral Health. ![]() They also offer specialized programs for veterans and LGBTQ+ individuals. Their services include outpatient and inpatient treatment, rehabilitation programs, housing and residential support, telehealth, and crisis services. Originally founded as Syracuse Brick House in 1967, the organization has since expanded to offer a wide range of mental health and addiction treatment services at multiple locations throughout New York State. ![]() Helio Health is a non-profit healthcare organization headquartered in Syracuse, New York. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |